Hotgen Biotech Co., Ltd (SHA: 688068), a biopharmaceutical company based in China, has announced that it has received clinical trial approval from the U.S. Food and Drug Administration (FDA) for its innovative drug candidate, SGC001.
SGC001, a monoclonal antibody (mAb) co-developed with Capital Medical University, is intended for the emergency treatment of acute myocardial infarction (AMI). This groundbreaking drug has the potential to be the first antibody targeting this critical condition to reach clinical trials globally, as no such antibody drug has yet been introduced to the market or even entered clinical use.- Flcube.com
